Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the mid-1980s, new molecular tools enabled the biology of cytokine expression and regulation to be studied. Our group uncovered a TNF-dependent cascade in active rheumatoid synovium, suggesting that TNF might be a therapeutic target; this concept was supported in an animal model of the disease. The proof of concept was a series of clinical trials, which have led to marked changes in the therapy of human rheumatoid arthritis and subsequently of other diseases. The work with TNF clearly demonstrated the importance of cytokines in medicine as well as the capacity of mAbs (or receptor fusion proteins) to be used long-term in large populations, thus changing the therapeutic landscape.

Original publication

DOI

10.4049/jimmunol.1090051

Type

Journal article

Journal

Journal of immunology (Baltimore, Md. : 1950)

Publication Date

07/2010

Volume

185

Pages

791 - 794

Addresses

Kennedy Institute of Rheumatology, Imperial College, London, United Kingdom. m.feldmann@imperial.ac.uk

Keywords

Animals, Humans, Arthritis, Rheumatoid, Methotrexate, Tumor Necrosis Factor-alpha, Antirheumatic Agents, Antibodies, Monoclonal, Treatment Outcome, Drug Therapy, Combination, Clinical Trials as Topic